What's Happening?
Johnson & Johnson has announced the completion of a clinical study for its OTTAVA robotic surgical system, which is designed for procedures such as gastric bypass. The study, involving 30 patients, evaluated the system's safety and performance, achieving
its primary endpoints. The results were presented at the 2026 American Society for Metabolic and Bariatric Surgery Annual Meeting. The OTTAVA system, which features four robotic arms integrated into a surgical table, aims to facilitate a range of soft-tissue surgeries. Johnson & Johnson is seeking FDA De Novo classification for the system.
Why It's Important?
The successful completion of this clinical study marks a significant milestone for Johnson & Johnson in the field of robotic surgery. The OTTAVA system's ability to perform complex procedures like gastric bypass without conversion to non-robotic methods highlights its potential to enhance surgical precision and patient outcomes. This development could lead to broader adoption of robotic systems in hospitals, improving surgical efficiency and reducing recovery times. The FDA's approval could further solidify Johnson & Johnson's position in the competitive market of surgical robotics.
What's Next?
Following the study, Johnson & Johnson will continue to pursue FDA approval for the OTTAVA system. If approved, the system could be introduced to hospitals across the U.S., potentially transforming surgical practices. The company may also conduct additional studies to expand the system's applications to other types of surgeries. The success of OTTAVA could encourage further innovation in robotic surgery, prompting competitors to enhance their own technologies.
